Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2018

Aug 14, 2018

BUY
$35.15 - $51.45 $57,329 - $83,914
1,631 Added 12.58%
14,600 $537,000
Q1 2018

May 15, 2018

BUY
$18.0 - $48.35 $233,442 - $627,051
12,969 New
12,969 $506,000

Others Institutions Holding ATRA

About Atara Biotherapeutics, Inc.


  • Ticker ATRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,362,304
  • Market Cap $1.13B
  • Description
  • Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...
More about ATRA
Track This Portfolio

Track Hbk Investments L P Portfolio

Follow Hbk Investments L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hbk Investments L P, based on Form 13F filings with the SEC.

News

Stay updated on Hbk Investments L P with notifications on news.